Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs
Artículo
Material complementario disponible
Artículo
DOAJ
Abstract Background Sorafenib has served as standard treatment for advanced hepatocellular carcinoma (HCC). Recently, several randomized controlled trials (RCTs) have explored the use of programmed cell death protein 1/p...
LCC LCC:Diseases of the digestive system. GastroenterologyIdioma eng
Material complementario disponibleEl enlace apunta a material asociado, anexos, tablas, datos o página complementaria. No se marca como libro/texto completo.
Material complementario